AVE.AX Avecho Biotechnology Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Feed
06:42
Sep 14
Sep 14
Tiny biotech, Phase 3 CBD insomnia, Sandoz partner
Author argues Avecho Biotechnology is a tiny biotech with a Phase 3 CBD-based insomnia drug and Sandoz already involved, giving it asymmetric risk/reward at around 0.009 per share. The catalyst is the Phase 3 program plus the stock's recent unexplained price movement after sitting dead for a long time. Author acknowledges the main risk is that this is a proper tiny biotech that could end badly, and has only thrown a small amount at it.
HIGH
09:37
Sep 13
Sep 13
Speculative micro-cap insomnia Phase 3 catalyst
The author bought a small position in Avecho Biotechnology, a tiny, thinly followed micro-cap, citing an ongoing Phase 3 insomnia drug program with Sandoz involved as the key catalyst. The stock has recently started moving after a long period of inactivity, and the author expects positive Phase 3 news could drive a sharp move. The author explicitly frames this as a lottery-ticket bet that could be genius or a total loss, acknowledging the high risk of clinical-stage failure.
MED
About AVE.AX Investor Commentary
Across the available history and selected sources, Buzzberg tracks AVE.AX (Avecho Biotechnology Limited) across 2 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Past 7 days, before deduplication: 2 bullish. Latest voices: u/Cyberlord1208.